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Background: The global burden of the major vascular diseases is projected to rise and to remain the dominant
non-communicable disease cluster well into the twenty first century. The Department of Health in England has
developed the NHS Health Check service as a policy initiative to reduce population vascular disease risk. The aims
of this study were to monitor population changes in cardiovascular disease (CVD) risk factors over the first year of
the new service and to assess the value of tailored lifestyle support, including motivational interview with ongoing
support and referral to other services.
Methods: Randomised trial comparing NHS Health Check service only with NHS Health Check service plus
additional lifestyle support in Stoke on Trent, England. Thirty eight general practices and 601 (365 usual care, 236
additional lifestyle support) patients were recruited and randomised independently between September 2009 and
February 2010. Changes in population CVD risk between baseline and one year follow-up were compared, using
intention-to-treat analysis. The primary outcome was the Framingham 10 year CVD risk score. Secondary outcomes
included individual modifiable risk measures and prevalence of individual risk categories. Additional lifestyle support
included referral to a lifestyle coach and free sessions as needed for: weight management, physical activity, cook
and eat and positive thinking.
Results: Average population CVD risk decreased from 32.9% to 29.4% (p <0.001) in the NHS Health Check only
group and from 31.9% to 29.2% (p <0.001) in the NHS Health Check plus additional lifestyle support group. There
was no significant difference between the two groups at either measurement point. Prevalence of high blood
pressure, high cholesterol and smoking were reduced significantly (p <0.01) in both groups. Prevalence of central
obesity was reduced significantly (p <0.01) in the group receiving additional lifestyle support but not in the NHS
Health Check only group.
Conclusions: The NHS Health Check service in Stoke on Trent resulted in significant reduction in estimated
population CVD risk. There was no evidence of further benefit of the additional lifestyle support services in terms of
absolute CVD risk reduction.
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Despite many advances in treatment, the global burden
of the vascular diseases (including heart disease, stroke
and other disorders with a strong vascular component,
such as diabetes and chronic kidney disease) is projected
to rise and to remain the dominant non-communicable
disease cluster well into the 21st century [1-3]. This chal-
lenge to global health has prompted calls for renewed
efforts to tackle the lifestyle and treatment inertia issues
that are known to be impediments to successful preven-
tion of these diseases [4]. Over the past 40 years since
the global pandemic of atherosclerotic diseases became
widely accepted [5], research support for the value of
prevention has been greatly strengthened but this evi-
dence has yet to translate to successful public health
policies that demonstrate a down-turn in the population
burden of these diseases. Evidence alone is insufficient
to effect change.
More recently, it has become clear that effective public
health policy for the prevention of the major vascular
diseases will require concerted partnership and action
among multiple agencies, both within and outside the
traditional health sector [6,7]. In a shift to a more con-
certed, multi-sector policy for prevention, the Depart-
ment of Health in England introduced the NHS Health
Check programme in 2009 [8]. Since this programme is
in its infancy there is a need for reliable evidence on re-
cruitment to the programme and outcomes following
implementation of the guidelines.
There is abundant evidence that lifestyle change can
have a beneficial effect on individual vascular disease
risk factors. For example, high blood pressure can be
prevented with dietary intervention alone [9], diabetes
can be prevented or delayed with diet and physical activ-
ity in combination [10] and population levels of choles-
terol can be reduced with diet change alone or in
combination with medication [11]. However, it has been
argued that, because of the cumulative effect of multiple
risk factors, vascular risk would be best managed using
multi-factorial estimates of absolute risk based on estab-
lished risk estimators such as the Framingham equations
for estimating cardiovascular risk [12,13]. Indeed, there
is research evidence to support the benefits of such an
approach [14-16] but routine use in clinical practice has
yet to be established. Further evidence is required to
convince patients and health professionals that greater
benefits can be achieved by adopting a multi-factorial
approach, coupling medications (e.g. for blood pressure
and/or cholesterol control) with more concerted efforts
to change established risk behaviours related to lifestyle,
such as tobacco use, unhealthy diet, insufficient physical
activity and excessive use of alcohol.
As far as we are aware, the NHS Health Check initia-
tive in England is the first national programme toattempt to develop a systematic and coordinated ap-
proach to the management of major vascular disease risk
at the population level. The initiative is led in most areas
by general practices, which are the custodians of clinical
data and the first points of call with regard to health
issues for most people in England. This paper evaluates
the change in population cardiovascular disease (CVD)
risk following implementation of NHS Health Check in
Stoke on Trent after one year of the programme. The
question of whether there is added value of lifestyle sup-
port over and above the basic health check in reducing
population CVD risk is also addressed.
Methods
Study design
A randomised trial design was used comparing patients
who received the NHS Health Check only service with
patients who received an NHS Health Check plus add-
itional support for lifestyle change. Full details of the
methods have been published elsewhere [17]. Modifica-
tions to the original protocol and a summary of the
details of methods pertinent to the research reported
here are summarised below. All participants gave written
informed consent and the study was approved by the
South Birmingham Research Ethics Committee, West
Midlands Region of England.
Settings and participants
Thirty eight general practices were recruited to the study
between September 2009 and February 2010. A total of
601 participants were recruited to the trial, 365 to the
NHS Health Check only group and 236 to the NHS
Health Check plus additional lifestyle support group.
Dedicated software, Oberoi Clinical Observations (Oberoi
Consulting, Derby, UK), was used to stratify practice lists
by estimated 10-year CVD risk. Patients with an esti-
mated CVD risk of ≥ 20% were considered eligible for in-
clusion in the trial. Each practice list was randomised
into trial groups by an independent researcher, blinded to
any further details of patients or practices. Practice nurses
or project support workers in each practice went through
their list, systematically contacting patients in batches of
20–50 depending on practice size, until either the recruit-
ment target for the practice had been reached or all eli-
gible patients had been invited. Up to three reminder
letters were sent before a non-response was recorded. Al-
location to group was only revealed once all details of the
trial had been explained to the patient and written
informed consent to participate had been given at the
end of the final NHS Health Check assessment visit.
Interventions compared
The NHS Health Check group received an NHS Health
Check and usual general practice care, including
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dependent upon the outcome of the health check but
did not receive additional lifestyle support. The NHS
Health Check plus additional lifestyle support group
received an NHS Health Check and were also offered
additional support for lifestyle change. This support,
which was based on the national Health Trainer motiv-
ational interview/counselling model, included: one to
one consultation with a lifestyle coach, the opportunity
to discuss, develop and negotiate a personalised health
improvement plan and lifestyle improvement priorities
identified by the patient and referral to free support ses-
sions for: weight management, physical activity, cook
and eat and positive thinking, as desired by the individ-
ual participant. Additional support (including up to six
hours of one to one contact if needed) was provided for
20 weeks in the first instance with ongoing support
available for up to a year if required. Full details of the
primary care interventions are given in the Primary Care
Toolkit [18].
Outcome measures
The primary outcome measure for the evaluation was
the Framingham 10-year CVD risk using the Joint Brit-
ish Societies’ Guidelines [19], which was the recom-
mended procedure at the time of conducting this
research. Secondary outcome measures included changes
in individual CVD risk factor categories (high blood
pressure, high cholesterol and smoking) as well as
changes in lifestyle related risk factors of weight, body
mass index (BMI), diet and physical activity. Blood pres-
sure, height, weight and waist circumference were mea-
sured in standardised fashion by trained nurses. Total
cholesterol, high density lipoprotein (HDL) and fasting
or random plasma glucose (for confirmation of diabetes
status, the nature of the test used depending on practice
preference) levels were measured as per protocol. For
the purposes of this evaluation, high blood pressure was
defined as having a systolic blood pressure ≥ 140 and a
diastolic blood pressure ≥ 90 mmHg, high cholesterol
was defined as having total cholesterol to HDL ratio ≥
4.5, overweight was defined as having BMI ≥ 25 and <
30 kgm-2 and obesity was defined as having BMI ≥ 30
kgm-2. Central obesity was defined from waist circumfer-
ence measurements as follows: males – waist circumfer-
ence ≥ 102 cm (Asian males ≥ 90 cm), females ≥ 88 cm
(Asian females ≥ 80 cm). Smokers were defined as those
who were current smokers or who had given up in the
last year. Finally, diet was categorised for each patient
into 1 – poor, 2 - average or 3 - good using guideline
diets outlined in the Primary Prevention Toolkit (Ap-
pendix 1c) and habitual physical activity was categorised
into one of 4 groups, 1 - inactive, 2 - moderately in-
active, 3 - moderately active and 4 -active, using theGeneral Practice Physical Activity Questionnaire [20]. It
is acknowledged that both the diet grade and exercise
grade measures are relatively crude and lack the sensitiv-
ity to detect subtle changes in either diet or physical ac-
tivity that may benefit health. On the other hand, they
are simple to use measures that capture the importance
of lifestyle to cardiovascular health and serve as a focus
for discussion and change within the context of a busy
general practice.
Sample size estimates
Based on a minimum expected effect size of 0.3 (from
Benner et al. [14]), an estimated intra-class correlation
coefficient (ratio of the variance between practices to the
total variance (within + between) practices) of 0.03, a
false positive error rate of 0.05 and statistical power of
0.8, we estimated that we would need to achieve a sam-
ple of 10 patients from each practice in each trial arm
for the majority of the general practices in Stoke on
Trent (target 46 of 55 practices – some practices did not
have compatible software) [21]. This would allow us to
detect a reduction in mean population CVD risk equat-
ing to about 5% of expected baseline level. Our original
sample size calculations were based on a cluster rando-
mised controlled trial design but, with the launch of the
NHS Health Check programme and its national roll-out
led by general practice just after the start of our evalu-
ation, it was not feasible on ethical or practical grounds
to continue with this design. On the basis that it was still
of value to monitor the potential effects of implementa-
tion of the NHS Health Check programme and to esti-
mate the value of additional lifestyle support, we decided
to proceed with a modified trial whereby patients were
randomised to groups within practices, accepting the po-
tential losses of attribution to treatment and to statistical
power that this would entail.
Statistical analysis
Details of our proposed approach to analysis have been
published previously [17]. In summary, multi-level re-
gression modelling was used to evaluate differences in
our primary outcome, 10-year CVD risk, between
groups and over time, accounting for clustering at the
practice level. Since the 10-year CVD risk variable was
positively skewed, the data were log transformed for in-
clusion in the analysis. Individual level variables included
in the model were age and gender, to account for pos-
sible variations in response to treatment for these factors
[22-24]. Practice level variables included were socio-
economic status of the practice population [25], practice
size and staggered recruitment group (SRG). The latter
was included to allow us to model the possibility of dif-
ferences arising from experience with delivering the
NHS Health Check service over time. Recruitment of
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year, which also included start-up and embedding of the
local NHS Health Check service. The SRG variable
allowed us to explore whether service effectiveness var-
ied over time. A three level model was developed using
the HML Software Version 6.08 (Scientific Software
International, Lincolnwood, IL, USA). Level 1 variables
were the repeated measurements within individuals by
group and time (baseline and 1-year), individual (level 2)
variables were age in years and gender and practice
(level 3) variables were as described above. Analysis was
performed on an intention-to-treat (ITT) basis, with last
available measure carried forward where data were miss-
ing at follow-up.
Cardiovascular risk (log transformed) was modelled
using a multi-level linear regression equation including
variables with the following coding:
Practice level factors
 Socio-economic status, IMDG – 1 More deprived, 2
More affluent
 Staggered recruitment group, SRG – 1 Recruited in
first group of practices. . . 5 Recruited in last group
of practices
 Practice size, PRACSIZE – 1 Small (<3500 patients),
2 Medium (≥3500 and < 7000), 3 Large (≥7000)
Individual level factors
 Age (years), AGE
 Gender, SEX – 0 Male, 1 Female
Identifier variables related to
 Group, GROUP – 0 NHS Health Check only, 1
NHS Health Check plus additional lifestyle support
 Time, TIME – 0 Baseline, 1 Follow-up at 1 year.
The model also included variance components, r0
representing variation associated with differences be-
tween individuals within practices, u00 representing vari-
ation associated with differences between practices and e
representing random (measurement) error.
The χ2 test was used to assess differences in categor-
ical variables between groups. T-tests were used to test
for differences between scale variables where the data
were normally distributed, otherwise non-parametric
tests were used. The Wilcoxon test and McNemar test
(for binary outcomes) were used to assess changes in
risk factor categories between baseline and the 1-year
follow-up.
A p-value of < 0.05 was considered statistically signifi-
cant in all tests and for regression model coefficients.Blinding
Researchers providing the intervention were masked to
follow-up data and staff collecting data from patients
were masked to treatment allocation. Participants
received information as per usual practice from their
general practitioner or practice nurse. The researcher re-
sponsible for statistical analysis (TC) was blinded to
treatment allocation until all data entry and checking
had been completed. Furthermore, all patient and prac-
tice identities were removed from any data included in
the analysis.
Results
The flow of patients throughout the trial is summarised
in Figure 1 and demographic details are displayed in
Table 1. A much larger than anticipated number of
patients contacted was ineligible for the trial (see
Excluded box in Figure 1). The 6416 patients with other
reasons for ineligibility included 3018 (30%) who did not
respond to at least three invitations, 3038 (30.2%)
patients who had already been seen by their GP and
were receiving some form of treatment and 360 (3.6%)
who were missing relevant details or had left the area.
Eligible participants (n=601) were randomised into two
groups, the NHS Health Check only group (n=365) and
the NHS Health Check plus additional lifestyle support
group (n=236). Baseline data were obtained for all parti-
cipants, apart from 15 waist circumference and 6 pulse
rate measurements. At follow-up, 70 (19%) participants
from the NHS Health Check only group and 45 (19%)
participants from the NHS Health Check plus additional
lifestyle support group had missing CVD risk scores
(primary outcome). Since the primary analysis was to be
carried out on an ITT basis, missing values were
replaced by carrying forward the last available measure-
ment. There were no significant differences between the
two groups on any of the demographic measures,
Table 1.
Baseline and 1-year follow-up measures for both
groups are compared in Table 2 on the basis of available
data only (best estimates of ‘on treatment’ effect). There
were no significant differences between the groups at
baseline except for weight, BMI and pulse rate (NHS
Health Check plus additional lifestyle support group
were on average 2.4 kg heavier, ~1 kgm-2 greater and 4/
minute higher respectively). This was confirmed in sep-
arate comparisons of change in CVD risk and individual
risk factors between groups. In terms of the comparison
of available follow-up data with baseline data, both
groups showed similar beneficial reductions in risk fac-
tors: about 7 mmHg in systolic blood pressure, 4mmHg
in diastolic blood pressure, 0.65 mmol/l in total choles-
terol level, 0.5 in total cholesterol/ HDL ratio and 2 cm
in waist circumference. Changes in HDL, weight and
Figure 1 Summary of screening, recruitment, randomisation and flow of patients throughout the evaluation.
Table 1 Demographic characteristics of sample groups
Characteristic Health
Check
group
Health
Check
plus group
Age (years) Mean (SD) 63.9 (6.5) 63.3 (6.4)a
Gender F 36 (9.9%) 32 (13.6%)a
M 329 (90.1%) 204 (86.4%)
Ethnicity White 355 (97%) 226 (95.8%)a
Other 10 (3%) 10 (4.2%)
Socio-economic statusb Deprived 161 (45.9%) 121 (52.2%)a
Intermediate 121 (34.5%) 68 (29.3%)
More affluent 69 (19.7%) 43 (18.5%)
a No significant difference between groups; SD–standard deviation; F-Female,
M-Male.
b Deprived-IMD deciles 1–3; Intermediate-IMD deciles 4–7; More affluent-IMD
deciles 8–10 [25].
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tion in BMI (overall) of 0.3 kgm-2 was noted. Changes in
absolute CVD risk were similar in both groups, showing
about a 10% reduction from mean baseline score, corre-
sponding to relative risks of 0.89 (0.87 – 0.92) in the
Health Check only group and 0.91 (0.88 – 0.94) in the
Health Check plus additional lifestyle support group
(comparing scores at 1 year with baseline).
A summary of the final fitted model is included in
Table 3. At the practice level, only socio-economic status
made a marginally significant contribution to explaining
the variation in CVD risk, with more affluent practices
having a tendency towards lower risk scores. As
expected, older age and male gender were associated
with increased CVD risk. There was no significant differ-
ence in CVD risk between comparator groups, whereas
CVD risk at the 1-year follow-up was significantly lower
than at baseline. On this basis, overall population mean
CVD risk was reduced from 31.1% to 27.8%, a reduction
Table 2 Comparison of baseline and 1-year follow-up measures by groupa
Baseline Follow-up
Health Check group Health Check plus group Health Check group Health Check plus group
Mean SD N Mean SD N Mean SD N Mean SD N
CVD risk baseline (%) 32.9 9.7 365 31.9 10.0 236 29.4d 9.7 295 29.2d 10.1 191
Systolic blood pressure (mmHg) 146.0 17.0 365 144.4 16.2 236 138.3d 14.7 314 138.7d 14.6 204
Diastolic blood pressure (mmHg) 84.9 9.5 365 85.3 9.6 236 80.5d 8.8 314 81.5d 8.9 204
Total cholesterol (mmol/l) 5.7 0.9 365 5.7 0.9 236 5.0d 1.0 308 5.1d 1.0 197
HDL cholesterol level (mmol/l) 1.2 0.3 365 1.2 0.3 236 1.2 0.3 298 1.2 0.3 192
Total cholesterol/ HDL cholesterol ratio 4.8 1.0 365 4.9 1.1 236 4.2c 1.1 300 4.4d 1.1 192
Weight (kg) 82.6b 13.8 365 85.0 14.5 236 82.8 13.5 313 84.3 14.5 200
Body mass index (kgm-2) 27.5b 4.1 365 28.7 5.0 236 27.6 4.1 313 28.4e 4.9 200
Waist circumference (cm) 99.5 11.8 355 101.3 11.2 231 97.9d 10.7 280 99.1d 11.4 168
Pulse rate (/minute) 70.9c 11.4 362 74.8 12.0 233
Fasting plasma glucose (mmol/l) 5.6 2.0 365 5.4 1.0 236
Height (cm) 173.0 8.1 365 172.5 8.3 236
a Comparisons carried out on the basis of available data only.
b Baseline comparison between groups, p < 0.05.
c Baseline comparison between groups, p < 0.001.
d Paired comparison (baseline versus 1-year follow-up) within group, p < 0.001.
e Paired comparison (baseline versus 1-year follow-up) within group, p < 0.01.
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other factors in the model.
The variance component between practices, u00,
though significant, was small, indicating that the vari-
ation in mean CVD risk between practices was small.
The variance component between individuals within
practices, r0, was larger and also significant.
Changes in the clinical measures between baseline and
the 1-year follow-up are shown in Table 4. Comparisons
in this case have been carried out on an ITT basis (bestTable 3 Summary of multi-level model fit to log transformed
Factor Coefficient
Intercept 2.512
Practice factors IMDG −0.079
SRG 0.000
PRACSIZE −0.026
Individual factors AGE 0.017
SEX −0.256
Grouping factors GROUP −0.007
TIME −0.111
Variance components
r0 0.055
e 0.036
u00 0.002
CVD-cardiovascular disease; df-degrees of freedom.
Grouping variables: IMDG-socio-economic status; SRG-staggered recruitment group
baseline or follow-up.
Variance components: r0-between individuals; u00-between practices; e-random erroestimates of whole population effect). There were no sig-
nificant differences between the groups on any of the
measures. However, both groups showed significant and
clinically valuable changes in CVD risk, systolic and dia-
stolic blood pressure, total cholesterol, total/HDL chol-
esterol ratio and waist circumference. Weight, BMI and
HDL were effectively unchanged.
Table 5 summarises the changes in relevant risk fac-
tors between baseline and follow-up. At the 1-year fol-
low-up, there was significant reduction in the number ofCVD risk data
Standard error T-ratio df p-value
0.154 16.322 34 <0.001
0.039 −2.021 34 0.051
0.009 0.028 34 0.978
0.017 −1.546 34 0.131
0.002 9.091 598 <0.001
0.033 −7.658 598 <0.001
0.023 −0.287 1194 0.774
0.015 −7.501 1194 <0.001
Standard deviation df p-value
0.235 561 <0.001
0.189
0.042 34 0.027
; PRACSIZE-practice size; AGE-age group; SEX-gender; GROUP-treatment; TIME-
r.
Table 4 Summary of changes (baseline – follow-up) in clinical measures (mean, 95% CI)a
Measure NHS HC only NHS HC plus Overall
CVD risk (%) 3.10b 2.80b 2.98b
(2.43, 3.76) (2.01, 3.58) (2.47, 3.48)
Systolic blood pressure (mmHg) 6.65b 5.64b 6.25b
(4.94, 8.36) (3.74, 7.53) (4.98, 7.53)
Diastolic blood pressure (mmHg) 3.56b 3.31b 3.47b
(2.61, 4.52) (2.25, 4.38) (2.76, 4.18)
Total cholesterol (mmol/l) 0.54b 0.56b 0.55b
(0.45, 0.64) (0.44, 0.68) (0.47, 0.62)
High density lipoproteins (mmol/l) −0.01 −0.01 −0.01
(−0.03, 0.00) (−0.03, 0.01) (−0.03, 0.00)
Total cholesterol/HDL ratio 0.42b 0.47b 0.44b
(0.33, 0.51) (0.35, 0.59) (0.37, 0.51)
Weight (kg) 0.23 0.51 0.34
(−0.24, 0.70) (−0.21, 1.24) (−0.06, 0.74)
Body mass index (kgm-2) 0.02 0.22d 0.10c
(−0.13, 0.17) (−0.03, 0.47) (−0.04, 0.23)
Waist circumference (cm) 1.19b 1.61b 1.36b
(0.60, 1.78) (0.90, 2.32) (0.90, 1.81)
CI-confidence interval; HC-Health Check; a Comparisons carried out on ITT basis; b p< 0.001; c p< 0.05; d p< 0.01.
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and who were smokers. Obesity was not significantly
changed but there was some evidence of beneficial
population change, where central obesity was reduced in
patients in the additional lifestyle support group and
overall. There was further evidence of beneficial lifestyle
change through improved diet and physical activity
scores in both treatment groups (Wilcoxon test on
ordered categories, p < 0.001). Mean diet score increased
from 2.1 to 2.4 (NHS Health Check only group) andTable 5 Comparison of changes in risk factor classification by
Risk factor Risk factor at baseline NHS HC
No
High blood pressure No 251
Yes 61
High cholesterol No 149
Yes 62
Smoking No 158
Yes 46
Obese No 271
Yes 10
Central obesity No 189
Yes 28
a p < 0.01, McNemar test.
NHS HC – NHS Health Check only; NHS HC plus – NHS Health Check plus additionafrom 2.2 to 2.45 (NHS Health Check plus additional life-
style support); mean physical activity score increased
from 2.65 to 2.8 (NHS Health Check only group) and
from 2.67 to 2.81 (NHS Health Check plus additional
lifestyle support).
Discussion
Main findings
Both groups of patients considered to be at high risk
(≥ 20%) of having a cardiovascular event within the nextgroup
only NHS HC plus Overall
Risk factor at follow-up
Yes No Yes No Yes
20a 158 14a 409 34a
33 35 29 96 62
18a 81 9a 230 27a
136 56 90 118 226
10a 111 3a 269 13a
151 29 93 75 244
11 147 6 418 17
73 9 74 19 147
15 96 5a 285 20a
123 25 105 53 228
l lifestyle support.
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tion in CVD risk and in established CVD risk factor pro-
files over the 1-year intervention period. These beneficial
changes were similar in the two groups. Thus, there was
no added value of additional lifestyle support, at least, in
terms of absolute cardiovascular risk and individual CVD
risk factor reduction. In principle, these findings support
the effectiveness of the NHS Health Check programme
delivered through general practice. However, as shown in
Figure 1 (Excluded box), overall uptake was low, indicat-
ing perhaps that population readiness to make change
was not as good as it ought to have been, given that all
patients screened and contacted had been identified from
practice records as being at high risk of experiencing a
CVD event.
A part of this lack of population readiness to make
change may be attributed to practice or community
readiness to support change. We should bear in mind
that this research was carried out during the early stages
of the national roll-out of new policy. For many prac-
tices, this was the first opportunity they had had to have
access to a full electronic search of the practice database
and a complete list of current ‘high CVD risk’ patients
to manage proactively. Although additional funding was
made available through a Locally Enhanced Service
agreement, there will undoubtedly have been a step
change in internal demand within each practice and in
external demand in the supporting community. Alterna-
tive modes of recruitment of patients may offer some
potential for increased efficiency and reduction of costs.
Some of these, for example bespoke drop-in clinics, op-
portunistic health checks or partial health checks, have
been piloted in the overall programme of research in
Stoke on Trent, of which this study is a part [26,27].
Coupled with general practice readiness, it is also true
that the type of client represented by a high CVD risk
patient may be quite different from the usual users of
community services. We did not have sufficient
resources to explore these aspects of service delivery
more fully within this research but they would appear to
warrant more detailed investigation.
The apparent lack of effectiveness of the lifestyle sup-
port programme could be due to the sub-optimal refer-
ral to the lifestyle coach, sub-optimal delivery of the
services referred to or poor compliance of patients with
the support sessions offered. Our data on referral to the
lifestyle coaches and the personal health plan goals set
by participants (not reported here) indicated that referral
to the lifestyle coach was good and valued by partici-
pants. Thus, future research aimed at improving the
contribution of additional lifestyle support for the reduc-
tion of CVD risk should focus on the delivery and com-
pliance with treatment issues of the support services
referred on to.In general, data collection, data quality, retrieval and
download were satisfactory for the NHS Health Check
process to work through general practice. That is not to
say that there were not some issues that need addres-
sing. However, the majority of patients who responded
to the invitation to attend for a vascular risk health
check had their risk score corroborated by their clinical
re-assessments.
What is already known on this topic
Previous researchers have demonstrated that reductions
in estimated CVD risk can be achieved with more con-
certed action to address multiple risk factors through
general practice [14,16] or lifestyle behaviours [15] but
our study is the first, we believe, to attempt to systemat-
ically embed multi-factorial risk reduction in general
practice across a whole city. It has been proposed that
such whole -of-system action will be needed to address
the growing challenge of chronic diseases, including
heart disease, cancer, stroke, diabetes and respiratory
diseases [7,28].
The importance and multi-factorial nature of CVD
risk are well established as is the multiplier effect of risk
factor combinations. On the other hand, public accept-
ance and health practitioner acceptance of the need for
population responsibility and action for change are not
widespread. Given that the majority of the population is
registered with and attends their doctor at least once an-
nually, general practice is well positioned to influence
patient choice and referral to treatment options and
other community services.
What this study adds
Routine scanning of electronic medical records to pro-
vide lists of high risk (for CVD in this instance) patients
provides opportunity for systematic management of
chronic disease populations through GP, and preventive
measures therefor. Overall, data quality was adequate
though most practice lists contained ‘ghost’ data and
missing or non-usable items, requiring varying degrees
of screening and cleaning before use. Approximately 8%
of those on the lists drawn from practice records could
not be re-contacted for administrative reasons, where ei-
ther key data were missing or records were not updated,
for example, for patients who had moved away from the
area or who had died. A further approximately 29% of
patients did not respond to the invitation to attend a
health check (with a minimum of two follow-up invita-
tions). This represents an area of uncertainty in that we
have no way of knowing whether these patients were
simply not interested in a health check and chose not to
respond or whether the invitations were never received.
Thus, about two thirds of those patients on lists com-
piled from practice databases were accessible and,
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service. The error or uncertainty in the remaining one
third of patients may imply an additional administrative
burden for practices to routinely assure data entry, to
check data for completeness and to archive redundant
data.
Data entry would also benefit from greater standard-
isation and more robust supporting software (with in-
built data checking where feasible). Free text entry, for
example, was very cumbersome to analyse for many of
the fields, including primary risk fields e.g. smoking sta-
tus, used in this research and consumed a significant
amount of resource simply to recode already entered
data. Notwithstanding the loss of efficiency, this process
is error prone and, bearing in mind that a single missing
datum could mean that a significant diagnosis or treat-
ment could be missed, would be best avoided.
Limitations
The national policy directive and launch of the NHS
Health Check service overtook our original cluster ran-
domised controlled trial design (which had been piloted
and planned in the two years preceding the national
programme launch). In effect, the NHS Health Check
service became the standard treatment for the popula-
tion of interest in our trial. Thus, instead of being a ran-
domised controlled trial it became a randomised
comparison of two treatments, both of which were rela-
tively new developments. This meant that we did not
have a control group against which to compare our two
treatments. This limits our ability to attribute effects to
treatments.
In addition, uptake was lower than anticipated, even
taking into consideration that the NHS Health Check
service was being implemented simultaneously across
the whole of general practice in Stoke on Trent. Thus,
recruitment to the trial was much less than target (35
versus 46 practices target; 601 versus 1840 patients tar-
get). Notwithstanding this point, significant reductions
(~10% of mean baseline score) were detected in both
groups. We attribute this positive outcome to a combin-
ation of greater effect size for both treatments and a
lower loss to follow-up (~20% actual versus 50%
estimated).
The choice of risk estimator, having a limited set of
risk factors, should also be considered. The Framingham
10-year CVD risk calculator, albeit the recommended
approach at the time our research was carried out,
includes just three modifiable risk factors: blood pres-
sure, cholesterol levels and smoking. It is possible that
this measure may lack the sensitivity to detect more sub-
tle effects of lifestyle changes such as increased physical
activity, better diet and weight loss that may take a
longer time to manifest than the one year of follow-upconsidered here. This may explain, in part, our inability
to detect an effect of the additional lifestyle support after
one year.
About 20% of data were missing at follow-up. Whilst
ITT analysis mitigates this problem to some extent, the
fact remains that this adds a degree of uncertainty to ef-
fect size (and confidence interval) estimates obtainable
from the research. Sophisticated methods of imputation
of missing data are available [29,30]. We did consider
imputation but rejected the idea because we felt that its
technical complexity and improved precision would not
justify the effort involved, given that, due to the launch
of a national policy initiative part way through the trial,
we were unable to maintain a control group for the
study.
Both treatment groups were recruited from within the
same practices. Each patient was recruited individually
and independently but we have no way of knowing
whether there was communication between patients in
different treatment groups that may have led to treat-
ment contamination. Furthermore, it was not feasible,
within available resources, to monitor every treatment,
and adherence to treatment, of every patient. Thus, we
were unable to differentiate independent effects of indi-
vidual treatments.
Finally, there was an inadvertent imbalance in the
number of participants in the two arms of the trial. This
came about because a number of patients withdrew from
the study after having given their written informed con-
sent but before they had left the clinic after their final
baseline health check visit. This was an unforeseen cir-
cumstance and presented us with an ethical dilemma –
patient choice or research rigour. We took the pragmatic
decision that we could not go against the patient’s choice
and so these patients were treated as if they had declined
to participate in the research. There were no apparent
differences in demographic and key clinical measures be-
tween our two groups but we have no way of knowing
whether other important biases may have been intro-
duced by this means. Certainly, there does seem to be a
bias in treatment preference since the choice to opt out
in this way was higher for those allocated initially to the
additional lifestyle support group. This observation adds
weight to our earlier point about there being a need to
consider population readiness for lifestyle change more
fully.
Conclusions
Introduction of the NHS Health Check service in Stoke
on Trent led to significant reductions in estimated popu-
lation cardiovascular disease risk and associated individ-
ual risk factors. There was no further reduction in risk
measures from the additional lifestyle support package
offered to patients. Uptake of the service was lower than
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all effectiveness (and cost-effectiveness) of this national
policy initiative. On the other hand, routine screening of
electronic medical records is viable and offers potential
for the proactive and systematic management of popula-
tion cardiovascular risk.
Abbreviation
BMI: Body mass index (weight (kg)/height (m)2); CI: Confidence interval;
CVD: Cardiovascular disease; df: Degrees of freedom; GP: General practice/
general practitioner; HC: Health Check; HDL: High density lipoprotein
(cholesterol); IMD: Index of multiple deprivation (2010), an area-based
measure of socio-economic status; ITT: Intention-to-treat analysis;
NHS: National health service in the united kingdom; SD: Standard deviation;
SRG: Staggered recruitment group (variable used to test the possibility of
differences arising from experience with delivering the NHS Health Check
service over time).
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